查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594337

單株抗體市場：按產品類型、生產類型、適應症和最終用戶分類 - 2025-2030 年全球預測

Monoclonal Antibodies Market by Source Type (Chimeric, Human, Humanized), Production Type (In Vitro, In Vivo), Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年單株抗體市值為1,262.6億美元，預計2024年將達到1,418.1億美元，複合年成長率為12.41%，到2030年將達到2,864.3億美元。

單株抗體 (mAb) 是實驗室製造的分子，旨在作為抗體的替代，增強或模擬免疫系統對細胞的攻擊。由於它對特定抗原具有高度特異性，因此是治療癌症、自體免疫疾病、感染疾病等多種疾病的高度可靠的治療方法。單株抗體的需求在於其標靶特異性，從而減少副作用並提高治療效果。其應用範圍廣泛，在疾病管理、診斷工具和研究藥物方面具有治療用途。最終用途範圍廣泛，包括製藥和生物技術領域、醫院和研究機構，推動了各種臨床和實驗環境的需求。市場成長受到慢性病增加、基因研究進步和醫療保健支出增加等因素的顯著影響。然而，高昂的製造成本、嚴格的監管以及可能的副作用都限制了市場的擴張。專注於這些創新治療方法的生物製藥公司的激增為市場相關人員提供了機會。此外，亞太地區由於醫療基礎設施的改善和投資的增加，市場正在擴大，前景良好。為了利用這些機會，公司應該投資先進的生物加工技術以降低成本並提高產量比率，並建立策略聯盟進行研發。同時，市場參與企業必須克服生物相似藥競爭和製造複雜性等挑戰。創新領域包括雙特異性和多特異性抗體等新型單株抗體、增強的遞送機制以及單株抗體與人工智慧等新技術的整合以實現個人化治療。因此，由於技術進步和不斷成長的醫療保健需求，單株抗體市場充滿活力並不斷發展，需要策略遠見和適應性策略來實現永續成長和競爭優勢。

主要市場統計
基準年[2023] 1262.6億美元
預測年份 [2024] 1418.1億美元
預測年份 [2030] 2864.3億美元
複合年成長率（%） 12.41%

市場動態：揭示快速發展的單株抗體市場的關鍵市場洞察

單株抗體市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大具有成本效益的生物相似藥單株抗體的傳播
    • 癌症和其他慢性疾病的發生率上升
    • 隨著技術先進的遺傳平台的出現，基因組學的研究和開發活動不斷增加
  • 市場限制因素
    • 治療性單株抗體價格昂貴
  • 市場機會
    • 年度核准顯著增加
    • 改善供應鏈和分銷網路
  • 市場挑戰
    • 當前製造和精製工藝的局限性

波特五力：駕馭單株抗體市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解單株抗體市場的外部影響

外部宏觀環境因素在塑造單株抗體市場表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解單株抗體市場的競爭狀況

單株抗體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣單株抗體市場供應商績效評估

FPNV定位矩陣是評估單株抗體市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪單株抗體市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對單株抗體市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 單株抗體作為具有成本效益的生物相似藥越來越受歡迎
      • 癌症和其他慢性疾病的發生率上升
      • 基因組學研究和開發活動的增加以及技術先進的遺傳平台的出現
    • 抑制因素
      • 治療性單株抗體價格昂貴
    • 機會
      • 年度核准數量顯著增加
      • 改善供應鏈和分銷網路
    • 任務
      • 目前製造和精製工藝的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依來源類型分類的單株抗體市場

  • 嵌合體
  • 人類
  • 人性化
  • 鼠

第7章依生產類型分類的單株抗體市場

  • 體外
  • In vivo

第8章以適應症分類的單株抗體市場

  • 自體免疫疾病
  • 癌症
  • 感染疾病
  • 發炎疾病
  • 微生物病

第9章單株抗體市場：依最終用戶分類

  • 醫院
  • 調查機構

第10章美洲單株抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區單株抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲單株抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie, Inc.
  • ADC Therapeutics SA
  • Almac Group Limited
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E8B1E

The Monoclonal Antibodies Market was valued at USD 126.26 billion in 2023, expected to reach USD 141.81 billion in 2024, and is projected to grow at a CAGR of 12.41%, to USD 286.43 billion by 2030.

Monoclonal antibodies (mAbs) are laboratory-made molecules designed to serve as substitute antibodies that can enhance or mimic the immune system's attack on cells. They are highly specific to a particular antigen, making them a reliable therapeutic tool in the treatment of various diseases, including cancers, autoimmune disorders, and infectious diseases. The necessity of monoclonal antibodies is driven by their target specificity, which reduces side effects and increases treatment efficacy. Applications are broad, encompassing therapeutic use in disease management, diagnostic tools, and as research agents. The end-use scope spans across the pharmaceutical and biotechnology sectors, hospitals, and research institutes, driving demand across a spectrum of clinical and experimental settings. Market growth is significantly influenced by factors such as increased prevalence of chronic diseases, advancements in genetic research, and rising healthcare expenditure. However, high production costs, stringent regulatory frameworks, and potential side effects pose limitations to market expansion. A rapidly increasing number of biopharmaceutical companies focusing on these innovative therapies presents opportunities for market stakeholders. Additionally, expanding markets in the Asia-Pacific region, driven by improved healthcare infrastructure and increased investment, offer lucrative prospects. To capitalize on these opportunities, companies should invest in advanced bioprocessing technologies to reduce costs and improve yield, while also engaging in strategic collaborations for research and development. Meanwhile, market players must navigate challenges such as biosimilar competition and manufacturing complexity. Areas of innovation include novel mAb formats such as bispecific and multispecific antibodies, enhancing delivery mechanisms, and integrating mAbs with emerging technologies like artificial intelligence to personalize treatments. Consequently, the mAb market is dynamic, with continuous evolution driven by technological advancements and growing healthcare demands, warranting strategic foresight and adaptive strategies for sustainable growth and competitive advantage.

KEY MARKET STATISTICS
Base Year [2023] USD 126.26 billion
Estimated Year [2024] USD 141.81 billion
Forecast Year [2030] USD 286.43 billion
CAGR (%) 12.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Monoclonal Antibodies Market

The Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
    • Rising incidence of cancer and other chronic diseases
    • Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
  • Market Restraints
    • Pricing of therapeutic mAbs are high
  • Market Opportunities
    • Substantial increase in the number of approvals per year
    • Improvements in supply chain and distribution network
  • Market Challenges
    • Limitation in current manufacturing and purification processes

Porter's Five Forces: A Strategic Tool for Navigating the Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Monoclonal Antibodies Market

A detailed market share analysis in the Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Monoclonal Antibodies Market

A strategic analysis of the Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie, Inc., ADC Therapeutics SA, Almac Group Limited, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source Type, market is studied across Chimeric, Human, Humanized, and Murine.
  • Based on Production Type, market is studied across In Vitro and In Vivo.
  • Based on Indication, market is studied across Autoimmune Diseases, Cancer, Infectious Diseases, Inflammatory Diseases, and Microbial Diseases.
  • Based on End-User, market is studied across Hospitals and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
      • 5.1.1.2. Rising incidence of cancer and other chronic diseases
      • 5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Pricing of therapeutic mAbs are high
    • 5.1.3. Opportunities
      • 5.1.3.1. Substantial increase in the number of approvals per year
      • 5.1.3.2. Improvements in supply chain and distribution network
    • 5.1.4. Challenges
      • 5.1.4.1. Limitation in current manufacturing and purification processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Monoclonal Antibodies Market, by Source Type

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized
  • 6.5. Murine

7. Monoclonal Antibodies Market, by Production Type

  • 7.1. Introduction
  • 7.2. In Vitro
  • 7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Infectious Diseases
  • 8.5. Inflammatory Diseases
  • 8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes

10. Americas Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Monoclonal Antibodies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Monoclonal Antibodies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie, Inc.
  • 3. ADC Therapeutics SA
  • 4. Almac Group Limited
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023